GO:0031989 bombesin receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031989 (bombesin receptor signaling pathway) describes a G protein-coupled receptor (GPCR) pathway triggered when bombesin-like neuropeptides bind to bombesin receptors, leading to regulation of downstream cellular processes such as transcription.
• The pathway is mediated by a family of receptors including GRPR (BB2), NMBR (BB1), BRS-3 (BB3) and the orphan bombesin receptor subtype-3, which couple to Gq/11 and activate phospholipase C, calcium mobilization and MAPK cascades.
• Bombesin receptor signaling is a well-recognized oncotarget: GRPR and NMBR are overexpressed in many cancers and drive proliferation, survival and migration through HER3 and MAPK-dependent mechanisms.
• Non-visual arrestins regulate GRP receptor signaling and endocytosis, providing a key desensitization and trafficking node within the pathway.
• BRS-3 remains an orphan receptor with emerging roles in lung cancer and energy homeostasis, making it a promising but still investigational target.
• CRISPR-based knockout, point-mutation, knock-in and overexpression models are essential to dissect the causal contribution of bombesin receptor pathway components in cancer and other diseases.
Description
The bombesin receptor signaling pathway (GO:0031989) is a biological process in which a bombesin-like peptide binds to a bombesin receptor, a member of the G protein-coupled receptor (GPCR) superfamily, and initiates a signaling cascade that ultimately regulates downstream cellular processes such as transcription. Bombesin-related peptides, including gastrin-releasing peptide (GRP) and neuromedin B (NMB), act as neurotransmitters and growth factors in the central nervous system and peripheral tissues, and their receptors are widely expressed in normal physiology and in multiple malignancies. Because this pathway sits at the interface of neuropeptide signaling and cancer cell proliferation, it has become a focal point for both mechanistic studies and therapeutic development. At the molecular level, bombesin receptor signaling is classically initiated by agonist binding to GRPR (also known as BB2), NMBR (BB1) or BRS-3 (BB3), which promotes guanine nucleotide exchange on Gq/11 proteins and activation of phospholipase C, leading to inositol trisphosphate production, calcium release and protein kinase C activation. These second messengers feed into mitogen-activated protein kinase (MAPK) cascades and other effector pathways that control gene expression, cell cycle progression and survival. The pathway is also subject to tight regulation by G protein-coupled receptor kinases and non-visual arrestins, which mediate desensitization and endocytosis of the receptor. For researchers, GO:0031989 provides a structured framework to study how neuropeptide GPCR signaling contributes to both normal physiology and disease. The pathway is particularly relevant in oncology, where bombesin receptor overexpression and autocrine/paracrine loops drive tumor growth and where receptor antagonists and radiolabeled bombesin analogs are being explored for imaging and therapy. Understanding the precise molecular steps, the genes involved and the regulatory checkpoints is essential for translating this knowledge into experimental models and clinical applications.
bombesin receptor signaling pathway At A Glance
| GO ID | GO:0031989 |
|---|---|
| GO term | bombesin receptor signaling pathway |
| Ontology | biological_process |
| Synonym | bombesin receptor signalling pathway |
| Definition | A G protein-coupled receptor signaling pathway initiated by a bombesin binding to its receptor, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| Major function | Transduces bombesin-like neuropeptide signals from the cell surface to intracellular effectors, regulating transcription, proliferation and survival. |
| Key receptors | GRPR (BB2), NMBR (BB1), BRS-3 (BB3) and related bombesin receptor subtypes. |
| Major signaling modules | Gq/11, phospholipase C, calcium, protein kinase C, MAPK, HER3 transactivation. |
| Regulatory proteins | Non-visual arrestins (beta-arrestin 1/2) mediate desensitization and endocytosis of GRP receptor. |
| Disease relevance | Lung cancer, prostate cancer, breast cancer, gastrointestinal cancers and other malignancies. |
What Is GO:0031989?
In our own words, GO:0031989 (bombesin receptor signaling pathway) is the series of molecular events that begins when a bombesin-like ligand binds to a bombesin receptor on the cell surface and ends with the regulation of a downstream cellular process, such as changes in transcription. The receptor is a G protein-coupled receptor that activates heterotrimeric G proteins, typically Gq/11, which in turn stimulate phospholipase C and generate second messengers like inositol trisphosphate and diacylglycerol. These signals propagate through calcium and protein kinase C to MAPK cascades and other effectors, ultimately altering gene expression and cell behavior. The pathway also includes desensitization and endocytosis steps mediated by arrestins, which shape the duration and intensity of the signal.
Why Is bombesin receptor signaling pathway Important in Cell Biology?
GO:0031989 is important because bombesin receptor signaling is a prototypical neuropeptide GPCR pathway that links extracellular cues to transcriptional programs controlling cell growth and survival, and because its dysregulation is directly implicated in cancer progression and other diseases. The pathway provides a mechanistic framework for understanding how GRP, NMB and related peptides act as autocrine or paracrine growth factors, and it offers multiple druggable nodes, including the receptors themselves, downstream kinases and arrestin-mediated trafficking. For researchers, this term organizes the genes, molecular functions and cellular outcomes that must be interrogated when studying neuropeptide-driven biology, and it guides the design of CRISPR models and pharmacological experiments.
• Bombesin receptor signaling is a major driver of proliferation in lung cancer cells, acting through HER3 and MAPK-dependent mechanisms.
• GRPR and NMBR are overexpressed in many human tumors, making them attractive targets for imaging and therapy with bombesin analogs.
• The orphan receptor BRS-3 is emerging as a potential new target in lung cancer and other malignancies.
• Non-visual arrestins regulate GRP receptor signaling and endocytosis, highlighting the importance of desensitization in pathway output.
• Bombesin-like peptides function as neurotransmitters and growth factors in the central nervous system and peripheral tissues.
• The pathway is a model system for understanding Gq/11-coupled GPCR signaling and its integration with MAPK cascades.
• Pharmacological characterization of selective hBRS-3 agonists has provided tools to dissect receptor subtype-specific functions.
• Radiolabeled bombesin derivatives are being developed for molecular imaging of bombesin receptor-expressing tumors.
• CRISPR-based models enable causal testing of bombesin receptor pathway genes in cancer and metabolic disease.
• Understanding this pathway may reveal combination strategies with HER3, MAPK or GPCR-targeted therapies.
What Happens During bombesin receptor signaling pathway?
Ligand binding and receptor activation
In simple terms: A bombesin-like peptide docks onto a bombesin receptor on the cell surface, switching the receptor on.
The pathway begins when a bombesin-like neuropeptide, such as gastrin-releasing peptide (GRP) or neuromedin B (NMB), binds to its cognate bombesin receptor, typically GRPR (BB2), NMBR (BB1) or BRS-3 (BB3). These receptors are members of the G protein-coupled receptor superfamily and undergo conformational changes upon agonist binding that allow them to act as guanine nucleotide exchange factors for heterotrimeric G proteins. Receptor subtype expression patterns and ligand selectivity determine which cells respond to which bombesin-like peptide, and this specificity is a key determinant of physiological and pathological outcomes.
G protein activation and second messenger generation
In simple terms: The activated receptor turns on a G protein, which then switches on an enzyme that makes messenger molecules inside the cell.
Agonist-bound bombesin receptors couple predominantly to Gq/11 family G proteins, promoting exchange of GDP for GTP on the G alpha subunit and dissociation from G beta-gamma dimers. The activated G alpha q subunit stimulates phospholipase C beta, which hydrolyzes phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C, together initiating a cascade of phosphorylation events that propagate the signal. These second messengers are the central biochemical nodes of the bombesin receptor signaling pathway.
MAPK cascade and transcriptional regulation
In simple terms: The signal travels through a chain of kinases to the nucleus, where it changes which genes are turned on or off.
Calcium and protein kinase C signals converge on the mitogen-activated protein kinase (MAPK) cascade, leading to activation of ERK1/2 and other MAPKs that translocate to the nucleus and regulate transcription factors. In lung cancer cells, bombesin receptor activation stimulates growth through HER3 with a MAPK-dependent mechanism, demonstrating that the pathway can transactivate receptor tyrosine kinases to amplify proliferative signals. This transcriptional output is the endpoint specified in the GO definition of GO:0031989, linking neuropeptide GPCR signaling to gene expression programs that control cell cycle progression, survival and migration.
Desensitization and endocytosis
In simple terms: After signaling, the receptor is switched off and pulled inside the cell to stop the signal.
Following activation, G protein-coupled receptor kinases phosphorylate the bombesin receptor, promoting recruitment of non-visual arrestins (beta-arrestin 1 and 2). Arrestin binding sterically uncouples the receptor from G proteins, mediating desensitization, and also targets the receptor for clathrin-mediated endocytosis. This regulatory step controls the duration and magnitude of bombesin receptor signaling and can also initiate arrestin-dependent signaling branches. Dysregulation of arrestin function can therefore alter pathway output and contribute to disease phenotypes.
Integration with other signaling pathways
In simple terms: The bombesin signal talks to other growth factor pathways to fine-tune the cell's response.
Bombesin receptor signaling does not operate in isolation; it intersects with receptor tyrosine kinase pathways such as HER3 and with other GPCR cascades. This crosstalk allows the pathway to modulate diverse cellular outcomes, including proliferation, survival and migration, depending on cellular context. The orphan receptor BRS-3 may also engage distinct effectors, and its pharmacology is an active area of investigation. Understanding these integration points is essential for predicting how pathway perturbations will affect cell behavior.
Key Genes Involved in GO:0031989 bombesin receptor signaling pathway
The following genes and proteins are core components or well-documented modulators of the bombesin receptor signaling pathway (GO:0031989).
| Gene | Major Role | Research Relevance |
|---|---|---|
| GRPR | Gastrin-releasing peptide receptor (BB2); primary bombesin receptor that binds GRP and activates Gq/11 signaling | Overexpressed in many cancers; target for imaging and therapy; model for GPCR desensitization |
| NMBR | Neuromedin B receptor (BB1); mediates NMB-induced signaling and calcium mobilization | Implicated in lung and other cancers; used to study receptor subtype selectivity |
| BRS3 | Bombesin receptor subtype-3 (BB3); orphan receptor with emerging roles in cancer and metabolism | Potential new target in lung cancer; pharmacology studied with selective agonists |
| GRP | Gastrin-releasing peptide; endogenous ligand for GRPR | Autocrine/paracrine growth factor in cancer; used to activate pathway in vitro |
| NMB | Neuromedin B; endogenous ligand for NMBR | Regulates NMBR-dependent signaling; studied in cancer and CNS |
| ARRB1 | Beta-arrestin 1; mediates desensitization and endocytosis of GRP receptor | Key regulator of pathway duration; knockout models reveal trafficking defects |
| ARRB2 | Beta-arrestin 2; non-visual arrestin involved in GRP receptor regulation | Modulates GPCR signaling and arrestin-biased responses |
| GNAQ | G alpha q subunit; couples bombesin receptors to phospholipase C | Central node for Gq/11-mediated signaling; target for pathway dissection |
| GNA11 | G alpha 11 subunit; alternative Gq/11 family member | Contributes to bombesin receptor signaling in specific cell contexts |
| PLCB1 | Phospholipase C beta 1; generates IP3 and DAG downstream of Gq/11 | Effector enzyme for second messenger production; knockout alters calcium signaling |
| PRKCA | Protein kinase C alpha; activated by DAG; phosphorylates downstream targets | Modulates MAPK activation and transcriptional output |
| MAPK1 | ERK2; terminal kinase of MAPK cascade activated by bombesin receptors | Readout of pathway activation; target for inhibitors in cancer studies |
| MAPK3 | ERK1; MAPK cascade component downstream of bombesin receptors | Used as phosphorylation readout in pathway experiments |
| ERBB3 | HER3; receptor tyrosine kinase transactivated by bombesin receptor signaling | Mediates lung cancer growth; target for combination therapy |
| EGFR | Epidermal growth factor receptor; often crosstalks with bombesin receptor signaling | Context-dependent modulator of proliferation |
| SRC | Proto-oncogene tyrosine kinase; can be activated downstream of GPCRs | Potential mediator of bombesin-driven signaling |
| MMP1 | Matrix metalloproteinase 1; may release growth factors in GPCR crosstalk | Implicated in tumor microenvironment remodeling |
| FOS | Immediate early gene; transcription factor induced by MAPK signaling | Readout of transcriptional regulation by bombesin receptors |
How Is bombesin receptor signaling pathway Regulated?
Bombesin receptor signaling is regulated at multiple levels. Agonist-induced phosphorylation by G protein-coupled receptor kinases promotes binding of non-visual arrestins, which desensitize the receptor and target it for endocytosis, thereby limiting signal duration. Arrestin-mediated internalization can also serve as a scaffold for alternative signaling branches, adding complexity to pathway output. At the level of second messengers, calcium and DAG levels are tightly controlled by pumps, channels and metabolic enzymes, and protein kinase C activity is balanced by phosphatases. Crosstalk with receptor tyrosine kinases such as HER3 and EGFR can amplify or redirect the signal, and MAPK phosphatases terminate ERK1/2 activation. In cancer cells, autocrine or paracrine production of bombesin-like peptides can sustain pathway activity, and receptor overexpression can sensitize cells to low ligand concentrations. These regulatory layers are critical for understanding how perturbations in GO:0031989 lead to disease.
bombesin receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRPR | Lung cancer, prostate cancer, breast cancer; proliferation and survival | GRPR knockout and overexpression in cancer cell lines; xenograft models |
| NMBR | Lung cancer and other solid tumors; NMB-induced signaling | NMBR knockout and point-mutation models; calcium imaging |
| BRS3 | Lung cancer; metabolic and neuroendocrine functions | BRS3 knockout and knock-in models; selective agonist studies |
| ARRB1/ARRB2 | GPCR desensitization and trafficking; cancer signaling | Arrestin knockout cell lines; receptor endocytosis assays |
| ERBB3 | HER3-mediated lung cancer growth downstream of bombesin receptors | ERBB3 knockout and point-mutation models; MAPK readouts |
Bombesin receptor signaling in lung cancer
Lung cancer cells frequently overexpress bombesin receptors, particularly GRPR and NMBR, and use bombesin-like peptides as autocrine or paracrine growth factors. Activation of these receptors stimulates proliferation through HER3 and MAPK-dependent mechanisms, and the orphan receptor BRS-3 has been proposed as a possible new target in lung cancer cells. Targeting bombesin receptor signaling, alone or in combination with HER3 or MAPK inhibitors, is an active area of preclinical investigation.
Bombesin receptor signaling in other solid tumors
Beyond lung cancer, bombesin receptors are implicated in prostate, breast, gastrointestinal and other solid tumors, where they contribute to proliferation, survival and migration. Radiolabeled bombesin analogs have been developed for molecular imaging of receptor-expressing tumors, demonstrating the clinical relevance of this pathway. These imaging agents also provide tools to monitor receptor expression and target engagement in preclinical models.
Bombesin receptor signaling in neuroendocrine and metabolic contexts
Bombesin-like peptides act as neurotransmitters and regulators of energy homeostasis, and BRS-3 in particular has been studied for its role in metabolic control. The pharmacology of selective hBRS-3 agonists has been characterized in native and transfected cells, providing a foundation for understanding receptor subtype-specific functions. Dysregulation of these pathways may contribute to neuroendocrine and metabolic disorders, although causal evidence in humans remains limited.
From bombesin receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GRPR drive tumor growth in vivo? | GRPR knockout or knockdown cancer cell lines in xenograft models |
| Which residues mediate ligand binding and G protein coupling? | Point-mutation knock-in of GRPR or NMBR in receptor-null cells |
| How does BRS-3 contribute to lung cancer phenotypes? | BRS3 knockout and overexpression models in lung cancer cells |
| What is the role of arrestin-mediated desensitization? | ARRB1/ARRB2 knockout cells with receptor endocytosis and signaling assays |
| Can HER3 transactivation be blocked to reduce bombesin-driven growth? | ERBB3 knockout or point-mutation models with MAPK readouts |
| How does receptor overexpression affect ligand sensitivity? | Tagged knock-in or overexpression of GRPR/NMBR in reporter cell lines |
How to Study the bombesin receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium mobilization assay | Intracellular calcium release downstream of Gq/11 activation | Receptor activation profiling and agonist/antagonist testing |
| IP3/DAG biosensors | Second messenger production by phospholipase C | Dissecting Gq/11 signaling dynamics |
| Phospho-ERK immunoblot | MAPK cascade activation | Testing pathway inhibitors and receptor mutants |
| Luciferase reporter assay | Transcriptional output of MAPK and other effectors | Measuring downstream gene regulation |
| Arrestin recruitment assay | Desensitization and receptor-arrestin interaction | Studying GRP receptor regulation and trafficking |
| Receptor internalization imaging | Endocytosis of bombesin receptors | Assessing arrestin-dependent trafficking |
| CRISPR knockout screen | Genes that modify pathway output | Discovery of novel regulators and crosstalk nodes |
| RNA-seq / proteomics | Transcriptional and proteomic changes | Global profiling of pathway responses |
Calcium mobilization and second messenger assays
Because bombesin receptors couple to Gq/11 and phospholipase C, calcium mobilization assays using fluorescent dyes or genetically encoded calcium indicators are standard methods to measure pathway activation. IP3 and DAG levels can be quantified by biochemical assays or biosensors to dissect second messenger dynamics. These methods are typically applied to native or transfected cells expressing GRPR, NMBR or BRS-3 and are useful for pharmacological profiling of agonists and antagonists.
MAPK and transcriptional reporter assays
Downstream MAPK activation is commonly assessed by immunoblotting for phosphorylated ERK1/2 or by luciferase reporters driven by MAPK-responsive promoters. Immediate early genes such as FOS can be measured by quantitative PCR or RNA-seq to capture transcriptional output. These readouts link receptor activation to the endpoint specified in GO:0031989 and are essential for testing pathway inhibitors.
Receptor trafficking and arrestin recruitment assays
To study desensitization and endocytosis, researchers use fluorescently tagged receptors, arrestin recruitment biosensors and internalization assays. These methods reveal how non-visual arrestins regulate GRP receptor signaling and trafficking and can be combined with knockout of ARRB1/ARRB2 to test causality. Imaging approaches such as confocal microscopy and total internal reflection fluorescence microscopy provide spatial and temporal resolution.
CRISPR screens and omics profiling
Genome-wide CRISPR knockout screens can identify genes that modify bombesin receptor signaling or its phenotypic outputs, while RNA-seq and proteomics can profile transcriptional and proteomic changes downstream of pathway activation. These approaches are particularly useful for discovering crosstalk nodes such as HER3 and for validating candidate targets in cancer models. Integrating screen data with pathway databases like QuickGO helps contextualize hits within GO:0031989.
How CRISPR Can Be Used to Study GO:0031989 bombesin receptor signaling pathway
Knockout
CRISPR knockout of bombesin receptor genes such as GRPR, NMBR or BRS3 provides a clean genetic test of their contribution to pathway activation and downstream phenotypes. Knockout of downstream effectors like ERBB3 or MAPK1 can reveal which nodes are required for proliferation and transcriptional regulation. Knockout of ARRB1/ARRB2 is used to study desensitization and endocytosis of the GRP receptor. These models are typically validated by sequencing and functional assays such as calcium imaging or phospho-ERK immunoblotting.
Point Mutation
Point-mutation knock-in allows precise interrogation of receptor residues involved in ligand binding, G protein coupling or phosphorylation by GRKs. For example, mutating predicted phosphorylation sites in GRPR can test their role in arrestin recruitment and desensitization. Point mutations in downstream kinases or adaptor proteins can dissect signaling specificity without abolishing protein expression. These models are particularly valuable when complete knockout is lethal or confounded by compensatory mechanisms.
Knock-in
Knock-in of tagged or reporter versions of bombesin receptors enables real-time tracking of receptor localization, trafficking and interaction with arrestins. Knock-in of disease-associated variants or constitutively active mutants can model pathological pathway activation. Reporter knock-ins, such as luciferase or fluorescent protein fusions, facilitate high-throughput screening of pathway modulators. These approaches complement pharmacological tools and provide spatial and temporal resolution in living cells.
Overexpression
Overexpression of bombesin receptors or their ligands in cell lines is widely used to sensitize cells to pathway activation and to model the receptor overexpression seen in cancers. Overexpression of GRP or NMB can create autocrine loops that drive proliferation and MAPK activation. Overexpression of BRS-3 in lung cancer cells has been used to study its oncogenic potential and pharmacology. These models are useful for testing antagonists, imaging agents and combination therapies.
How EDITGENE Supports bombesin receptor signaling pathway Research
Researchers studying bombesin receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation, downstream transcription or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based cell model services that enable precise, reproducible and scalable experiments for dissecting GO:0031989 and its associated genes.
Contact EDITGENE today to design your custom CRISPR model for bombesin receptor signaling pathway research.
Frequently Asked Questions About bombesin receptor signaling pathway
What is GO:0031989 bombesin receptor signaling pathway?
GO:0031989 is a Gene Ontology biological process term describing the G protein-coupled receptor signaling pathway initiated by bombesin binding to its receptor and ending with regulation of a downstream cellular process such as transcription.
What genes are involved in bombesin receptor signaling pathway?
Key genes include GRPR, NMBR, BRS3, GRP, NMB, ARRB1, ARRB2, GNAQ, GNA11, PLCB1, PRKCA, MAPK1, MAPK3 and ERBB3.
Which receptors mediate bombesin receptor signaling?
The pathway is mediated by bombesin receptors including GRPR (BB2), NMBR (BB1) and the orphan receptor BRS-3 (BB3), which couple to Gq/11 proteins.
How is bombesin receptor signaling regulated?
It is regulated by G protein-coupled receptor kinases and non-visual arrestins, which desensitize the receptor and promote endocytosis, as well as by second messenger metabolism and MAPK phosphatases.
What diseases are associated with bombesin receptor signaling?
The pathway is implicated in lung cancer, prostate cancer, breast cancer, gastrointestinal cancers and other solid tumors, as well as neuroendocrine and metabolic contexts.
How can I study bombesin receptor signaling in the lab?
Common methods include calcium mobilization assays, phospho-ERK immunoblotting, transcriptional reporter assays, arrestin recruitment assays and CRISPR knockout screens.
What is the role of BRS-3 in bombesin receptor signaling?
BRS-3 is an orphan bombesin receptor subtype that has been proposed as a possible new target in lung cancer and is studied with selective agonists.
Can bombesin receptors be used for tumor imaging?
Yes, radiolabeled bombesin analogs have been developed for molecular imaging of bombesin receptor-expressing tumors.
What is the role of arrestins in bombesin receptor signaling?
Non-visual arrestins mediate desensitization and endocytosis of the GRP receptor, shaping the duration and intensity of the signal.
How does bombesin receptor signaling activate MAPK?
Activation of Gq/11 and phospholipase C leads to calcium and DAG signals that converge on the MAPK cascade, often with HER3 transactivation in cancer cells.
Conclusion
GO:0031989 (bombesin receptor signaling pathway) is a well-defined biological process that connects bombesin-like neuropeptide signals to transcriptional and proliferative programs through Gq/11-coupled GPCRs, second messengers and MAPK cascades. Its dysregulation is implicated in multiple cancers, and the pathway offers numerous targets for pharmacological and genetic intervention. Understanding the genes, regulatory mechanisms and disease links of this pathway is essential for both basic and translational research. CRISPR-based cell models, including knockout, point-mutation, knock-in and overexpression, provide powerful tools to dissect the causal roles of bombesin receptor pathway components. EDITGENE offers end-to-end services to design, generate and validate these models, accelerating discoveries in neuropeptide signaling and cancer biology.
References
- 1. Schumann M et al.. 2008. Function of non-visual arrestins in signaling and endocytosis of the gastrin-releasing peptide receptor (GRP receptor).. Biochem Pharmacol 75(5):1170-85 PMID: 18199425
- 2. Lee L et al.. 2020. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.. Biochim Biophys Acta Mol Cell Res 1867(4):118625 PMID: 31862538
- 3. Moreno P et al.. 2018. A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.. Peptides 101:213-226 PMID: 29410320
- 4. Leung K. 2004. [(18)F]Fluorobenzyl-bombesin[7-14]-c(RGDyK).. PMID: 20641919
- 5. Leung K. 2004. (99m)Tc-Hydrazinonicotinyl(tricine)(TPPTS)-Glu-c(RGDyK)-bombesin[7-14]NH(2).. PMID: 23166958
- 6. Moody TW et al.. 2018. Neuropeptide G Protein-Coupled Receptors as Oncotargets.. Front Endocrinol (Lausanne) 9:345 PMID: 30008698
- 7. Sancho V et al.. 2010. Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.. Peptides 31(8):1569-78 PMID: 20438784
- 8. Shan L. 2004. (99m)Tc((v))O-Gly-Gly-Cys-Orn-Orn-Orn-Bombesin[2-14].. PMID: 20641903
